Figure 1




Figure 2



4500
4000
3500
3000
2500
2000
1500
1000
MFI (PE)
1e-15
1e-14
1e-13
1e-12
1e-11
1e-10
1e-9
1e-8
Concentration (M)
EC50= 10 pM

Figure 3



ECDR2 competes with IFNαA Induced pSTAT1 Activity
MFI (PE)
3000
2800
2600
2400
2200
2000
1800
1600
1400
1e-11
1e-10
1e-9
1e-8
1e-7
1e-6
1e-5
Concentration (M)
ECDR2, IC50 = 4.1 nM, Rsqr = 0.99225065

Figure 4

Effect of Endotoxin on pSTAT1 Assay (THP-1)




Figure 5



1.0
0.8
0.6
0.4
0.2
0.0
OD 490nm
IC50=0.4 pM
10-16
10-15
10-14
10-13
10-12
10-11
10-10
10-9
IFNαA (M)

Figure 6

Effect of Endotoxin on Anti-proliferation Assay (Daudi)




Figure 7



540
520
500
480
460
440
420
400
380
MFI (APC)
EC50= 0.5 nM
1e-13
1e-12
1e-11
1e-10
1e-9
1e-8
1e-7
1e-6
IFNαA (M)

Figure 8



pTyk2
8000
7000
6000
5000
4000
3000
MFI (PE)
1e-12
1e-11
1e-10
1e-9
1e-8
1e-7
Sigma IFNαA
pTyk2, EC50 = 0.7 nM, Rsqr = 0.98308841

Figure 9



6His-M16-30K PEG
6His-I24-30K PEG
6His-F27-30K PEG
6His-N45-30K PEG
6His-N65-30K PEG
6His-E78-30K PEG
6His-E107-30K PEG
6His-R125-30K PEG
6His-K134-30K PEG
Pegasys
OD560-690
3.5
3
2.5
2
1.5
1
0.5
0
50
25
12.5
6.25
3.125
1.56
0.78
0.39
0.19
0.09
0.04
0
IFN (ng/ml)

Figure 10



70
60
50
40
30
20
10
0
CFU-GM Colony Count
19800.00
15488.17
12589.25
9900.00
7762.47
6309.57
4950.00
3890.45
3630.78
3162.28
2454.71
1949.84
1778.28
1584.89
1258.93
977.24
891.25
794.33
446.68
223.87
213.80
107.15
53.70
0.00
International Units
Pegasys
I24
N65
E78
E107

Figure 11



Improved Anti-Viral Potency
Anti-viral IC50
13
12
11
10
9
8
7
6
5
4
3
2
1
0
Worse than PEGASYS
PEGASYS
Potential 5x Therapeutic
Window Improvement
5 X Improvement in Anti-viral Potency
K134
E107
I24

Figure 12



Pegasys, BFU-E
BFU-E
60
50
40
30
20
10
0
-10
0.001
0.01
0.1
1
10
100
Pegasys (ug/ml)
ug/ml vs BFU-E, IC50 = 0.701026 ug/ml, Rsqr = 0.96107555
Controls

Figure 13

Pegasys, CFU-GM




Figure 14



Pegasys, Total CFC
Total-CFC
180
160
140
120
100
80
60
40
20
0
0.001
0.01
0.1
1
10
100
Pegasys (ug/ml)
ug/ml vs Total CFC, IC50 = 1.9607 ug/ml, Rsqr = 0.99463526
Control

Figure 15



Ribavirin, BFU-E
BFU-E
70
60
50
40
30
20
10
0
-10
0.001
0.01
0.1
1
10
100
1000
10000
Ribavirin (ug/ml)
ug/ml vs BFU-E, IC50 = 0.666571 ug/ml, Rsqr = 0.96209246
Control

Figure 16



Ribavirin, CFU-GM
CFU-GM
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
100
1000
10000
Ribavirin, ug/ml
ug/ml vs CFU-GM, IC50 = 0.830192 ug/ml, Rsqr = 0.99099360
Control

Figure 17



Ribavirin, Total-CFC
Total-CFC
180
160
140
120
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
100
1000
10000
Ribavirin (ug/ml)
ug/ml vs Total-CFC, IC50 = 1.041 ug/ml, Rsqr = 0.98344924
Control

Figure 18



M-M16-30K
M-I24-30K
M-F27-30K
M-H34-30K
M-G37-30K
Pegasys
OD560-690
3
2.5
2
1.5
1
0.5
0
50
25
12.5
6.25
3.125
1.56
0.78
0.39
0.19
0.09
0.04
0
IFN (ng/ml)

Figure 19







Figure 20




I




II



III





IV